权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

virtual-reality 3D interactive for the teleoperation of robotic systems

用于机器人系统远程操作的虚拟现实 3D 交互

基本信息

批准号：
293236-2005
负责人：
Yang, Xiaoli
金额：
$ 1.29万
依托单位：
Lakehead University
依托单位国家：
加拿大
项目类别：
Discovery Grants Program - Individual
财政年份：
2005
资助国家：
加拿大
起止时间：
2005-01-01 至 2006-12-31
项目状态：
已结题

来源：
https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=307894
关键词：
virtual reality 3D interactive teleoperation

项目摘要

No summary - Aucun sommaire

没有总结- Aucun sommaire

项目成果

期刊论文数量（0）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

数据更新时间：{{ journalArticles.updateTime }}

DOI：
{{ item.doi }}
发表时间：
{{ item.publish_year }}
期刊：
{{ item.journal_name }}
影响因子：
{{ item.factor }}
作者：
{{ item.authors }}
通讯作者：
{{ item.author }}

数据更新时间：{{ journalArticles.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ monograph.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ sciAawards.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ conferencePapers.updateTime }}

作者：
{{ item.author }}

数据更新时间：{{ patent.updateTime }}

Yang, Xiaoli其他文献

Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC-ACS (improving care for cardiovascular disease in China-acute coronary syndrome) project.

DOI：
10.1186/s40001-023-01025-6
发表时间：
2023-02-02
期刊：
EUROPEAN JOURNAL OF MEDICAL RESEARCH
影响因子：
4.2
作者：
Wang, Yintang;Geng, Yu;Zhang, Ou;Xu, Qin;Xue, Yajun;Zhou, Boda;Zhang, Ping;Li, Aihua;Li, Bao;Xu, Biao;Han, Guangshu;Li, Bin;Liu, Bin;Wang, Bin;Fu, Bing;Yu, Bo;Yang, Bosong;Luo, Caidong;Wang, Changqian;Liu, Changyong;Liang, Chuanliang;Gao, Chuanyu;Lai, Chunlin;Wang, Chuntong;Zhang, Chunyan;Wu, Chunyang;Zhang, Congliang;Bin, Cui;Huang, Lan;Peng, Daoquan;Xu, Dawen;Wu, Di;Zhu, Dongmei;Chai, Dongsheng;Li, Dongyan;Tang, Fakuan;Xiao, Jun;Zhao, Fang;Huang, Fangfang;Meng, Fanju;Li, Fengwei;Gan, Fudong;Xu, Gang;Sang, Gengsheng;Ma, Genshan;Zhang, Guixia;Tao, Guizhou;Li, Guo;Chen, Guoduo;Xin, Guoqin;Li, Guoqing;Fu, Guosheng;Chen, Guoxiong;Lin, Hailong;Guo, Haiping;Lin, Haiyun;Jiang, Hong;Liu, Hong;Luan, Hong;Zhang, Hong;Deng, Honghua;Li, Hongwei;Wang, Honhju;Liu, Hualing;Dong, Hui;Liu, Hui;Zhang, Huifang;Wang, Huifeng;Chu, Huimin;Xi, Jiabin;Yang, Jian;Ye, Jianfeng;Li, Jianhao;Tao, Jianhong;Liu, Jianwen;Yang, JiaoMei;Ding, Jiawang;Tong, Jiayi;Chen, Jie;Jiang, Jie;Yang, Jie;Li, Jifu;Yan, Jinchuan;Hu, Jing;Xu, Jing;Wang, Jingfeng;Diao, Jinglan;Zhao, Jingshan;Wei, Jinru;Yi, Jinxing;Su, Jinzi;Tang, Jiong;Chen, Jiyan;Yin, Jiyan;Fan, Juexin;Guan, Jun;Ge, Junbo;Liu, Junming;Deng, Junping;Fang, Junping;Li, Junxia;Chen, Kaihong;Luo, Kalan;Wu, Keng;Ji, Lang;Li, Lang;Jiang, Li;Wei, Li;Meng, Lijun;Ma, Likun;Tang, Lilong;Wang, Lin;Wei, Lin;Li, Ling;Tao, Ling;Yang, Liqiong;Wu, Lirong;Zhang, Man;Chen, Kaiming;Lai, Meisheng;Tian, Miao;Bai, Mingcheng;Han, Minghua;Chen, Moshui;Liang, Naiyi;Jia, Nan;Zhang, Peiying;Qu, Peng;Zhang, Pengfei;Chen, Ping;Hou, Ping;Xie, Ping;Dong, Pingshuan;Wu, Qiang;Xie, Qiang;Zhong, Qiaoqing;Wang, Qichun;Su, Qinfeng;Chang, Rong;Lin, Rong;Zhao, Ruiping;Jia, Shaobin;Nie, Shaoping;Ye, Shaowu;He, Shenghu;Chen, Shengyong;Ma, Shixin;Li, Shuangbin;Xin, Shuanli;Xia, Shudong;Zhang, Shuhua;Qu, Shuqiu;Ma, Shuren;Wang, Siding;Li, Songbai;Luo, Suxin;Liu, Tao;Zhang, Tao;Tuo, Tian;Li, Tianchang;Yang, Tianlun;Du, Tianmin;Wu, Tongguo;Liu, Wei;Mao, Wei;Tuo, Wei;Wang, Wei;Jiang, Weihong;Huang, Weijian;Liu, Weijun;Fan, Weiqing;Xu, Weiting;Lin, Wenhua;Su, Xi;Chen, Xia;Zhang, Xianan;Fu, Xianghua;Yang, Xiangjun;Zhao, Xianxian;Ma, Xiaochuan;Sun, Xiaofei;Wang, Xiaojun;Li, Xiaolan;Li, Xiaolei;Yang, Xiaoli;Chen, Xiaoping;Zhang, Xiaoqin;Cheng, Xiaoshu;Peng, Xiaowei;Ma, Xiaowen;Qi, Xiaoyong;Feng, Xiaoyun;Chen, Ximing;Tang, Xin;Tang, Xingsheng;Zhao, Xingsheng;Chen, Xiufeng;Li, Xudong;Li, Xue;Liu, Xuebo;Peng, Xuemei;Han, Yaling;Wang, Yan;Niu, Yanbo;Yu, Yang;Zheng, Yang;Wang, Yanli;Zheng, Yanlie;Guo, Yansong;Yang, Yanzong;Huang, Yi;Liu, Yin;Guo, Ying;Luo, Yingchao;Hao, Yinglu;Sun, Yingxian;Lin, Yingzhong;Ma, Yitong;Guo, Yong;Li, Yong;Li, Yongdong;Zhang, Yonglin;Jin, Yuanzhe;Li, Yue;Huang, Yuehua;Sun, Yuemin;Yang, Yuheng;Zhu, Yuhua;Shi, Yuhuan;Zhao, Yulan;Hou, Yuqing;Zheng, Zeqi;Xu, Zesheng;Ouyang, Zewei;He, Zeyuan;Lv, Zhan;Li, Zhanquan;He, Zhaofa;Ji, Zheng;Zhang, Zheng;Ji, Zhenguo;Su, Zhenqi;Yang, Zhenyu;Ou, Zhihong;Yang, Zhijian;Yang, Zhiming;Wang, Zhirong;Song, Zhiyuan;Wang, Zhongshan;Yuan, Zuyi
通讯作者：
Yuan, Zuyi

Synthesis and DNA cleavage activity of triazacrown-anthraquinone conjugates

三氮杂冠-蒽醌缀合物的合成和DNA切割活性

DOI：
10.1039/c0nj00347f
发表时间：
2010-11
期刊：
New Journal of Chemistry
影响因子：
3.3
作者：
Liu, Fang;Lu, Guo-Yuan;Wei, Li;Yang, Xiaoli;Xu, Weihong;Yang, Lian;Jia, Zhao-Li
通讯作者：
Jia, Zhao-Li

The oral microbiome of patients with ischemic stroke predicts their severity and prognosis.

DOI：
10.3389/fimmu.2023.1171898
发表时间：
2023
期刊：
FRONTIERS IN IMMUNOLOGY
影响因子：
7.3
作者：
Sun, Wenbo;Huang, Shengwen;Yang, Xiaoli;Luo, Yufan;Liu, Luqiong;Wu, Danhong
通讯作者：
Wu, Danhong

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.

DOI：
10.3389/fonc.2022.1010726
发表时间：
2022
期刊：
FRONTIERS IN ONCOLOGY
影响因子：
4.7
作者：
Luo, Jia;Gao, Benjian;Lin, Zhiyu;Fan, Hua;Ma, Wen;Yu, Danfei;Yang, Qian;Tian, Jing;Yang, Xiaoli;Li, Bo
通讯作者：
Li, Bo